Checked processes every Belgian company, act by act, from the Belgian Official Gazette. The data below is real and verified, this company's full, act-by-act verified dossier is still being assembled.
Summary
Conclusion
the dossier summarised in one paragraphThe computed 12-month bankruptcy probability of Chemist EU is 2.0% (moderate). The 2025 annual accounts show negative equity (€-125k) and a net result of €-73k. Equity is shrinking by ~16.4% per year across the filed fiscal years. Its solvency ranks better than 5% of 30 sector peers (fiscal year 2025). The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 3 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Signals
1 signal · with evidenceSignals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.
Trust signals
2 signalsAdministrative Flags
Financials
Annual accounts & ratios
Source: NBB · 2025How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -73.1% | 46.2% | |
| Net result | €-73k | €11k | |
| Equity | €-125k | €40k | |
| Gross operating margin | €-66k | €49k | |
| Total assets | €170k | €188k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €-71k |
| Net profit | €-73k |
| Cash flow | €-71k |
| Staff costs | - |
| Income taxes | - |
| Dividends | - |
| Total assets | €170k |
| Equity | €-125k |
| Debt | €295k |
| of which ≤ 1y | €295k |
| of which > 1y | - |
| Working capital | €-132k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 0.55 |
| Quick ratio | 0.13 |
| Working capital ratio | -77.4% |
| Solvency | -73.1% |
| Debt / equity | -2.37 |
| Long-term debt ratio | - |
| Interest coverage | -182.12 |
| Gross margin | - |
| Net margin | - |
| ROA | -43.1% |
| ROE | 58.9% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €170k |
| Fixed assets | 21/28 | €7k |
| Tangible fixed assets | 22/27 | €4k |
| Financial fixed assets | 28 | €4k |
| Current assets | 29/58 | €163k |
| Stocks & contracts in progress | 3 | €125k |
| Amounts receivable within one year | 40/41 | €7k |
| Cash & bank | 54/58 | €31k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €170k |
| Equity | 10/15 | €-125k |
| Contributions / capital | 10/11 | €30k |
| Accumulated profits (losses) | 14 | €-155k |
| Amounts payable | 17/49 | €295k |
| Amounts payable within one year | 42/48 | €295k |
| Trade debts payable within one year | 44 | €3k |
| Income statement | ||
| Gross operating margin | 9900 | €-66k |
| Operating result | 9901 | €-73k |
| Financial income | 75 | €229 |
| Financial charges | 65 | €387 |
| Result before taxes | 9903 | €-73k |
| Net result for the period | 9904 | €-73k |
| Result to be appropriated | 9905 | €-73k |
Health barometer
FY 2025 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Structure & network
Locations & real estate
Registered office
on the map · from the address registerEstablishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11807G1698/00E000 | Flanders | 9,863 m² | 1 · 1,162 m² | 52.5 m · 14 fl. |
Publications
Lifecycle & Insolvency Signals
Belgisch Staatsblad · acts
3 acts09-10-2025 Registered office moved from Niel to Antwerpen
- Galileilaan 90 A1, 2845 Niel → Noorderlaan 139; 2030 Antwerpen
31-10-2023 Mandate of Jean-Claude DE GHEEST as director expired
- Jean-Claude DE GHEEST, Bestuurder
06-12-2022 TYTARENKO Anton appointed as director
Analysis
Snowflake analysis
financial profile on 5 axesMixed profile: strong on profitability, weaker on health.
All 5 axes are computed from data Checked has read.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector, nearest firstCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameNL | Chemist EU |